PPD And VirtualScopics Establish Strategic Alliance For Medical Imaging Services

PPD, Inc. (NASDAQ: PPDI) and VirtualScopics, Inc. (NASDAQ: VSCP) today announced a strategic alliance to deliver a comprehensive set of clinical and medical imaging services that will enable biopharmaceutical companies to make faster, more confident decisions on the development of their oncology compounds, creating time and cost efficiencies.

The partnership will provide seamless integration of technologies and processes, giving biopharmaceutical companies near real-time, consistent and reliable medical imaging information to expedite their drug development programs. The integration of services between the two companies will establish a more efficient, tailored approach across several key areas of the clinical trial process, including study startup, screening and enrollment, accurate determination of endpoints for radiographic response and progression, management of imaging data and proactive risk management.

“VirtualScopics’ advanced technology and data-driven image analysis builds on PPD’s strong clinical development offerings, and this alliance demonstrates our commitment to leveraging partnerships that bring technological innovation to our clients,” said Mike Wilkinson, executive vice president and chief information officer of PPD.

The alliance with VirtualScopics will enhance PPD’s ability to provide clients with the full service, integrated solutions needed to progress drug development from early phase to regulatory approval through an innovative, patented algorithm-based approach to image processing and biomarker measurement. In return, PPD’s strong operational and medical expertise and global footprint offer VirtualScopics an opportunity to integrate medical imaging and clinical services and grow its strong customer base.

“As a global leader in Phase I-IV oncology research and development, we understand the importance of medical imaging technologies to our clients in advancing their drug development programs,” said David Grange, chief executive officer of PPD. “This partnership expands our ability to deliver the most innovative, highest quality full development services in oncology, and we are pleased to partner with VirtualScopics, which has an exemplary reputation in this area.”

1 2 Next › Last »